Literature DB >> 21331640

[Pulmonary arterial hypertension].

F Reichenberger1, R Voswinckel.   

Abstract

Pulmonary arterial hypertension is a chronic disorder of the pulmonary circulation characterized by an increased pulmonary artery pressure and an impaired cardiac function. It can present as idiopathic form or associated with several systemic diseases. Typical symptoms include progressive dyspnoea and exercise intolerance. When pulmonary arterial hypertension is suspected, echocardiography is the key investigation for noninvasive assessment of the disease. The diagnosis requires an invasive measurement of pulmonary hemodynamics by right heart catheterization. Treatment is based on general measures and application of pulmonary vasoactive compounds, such as prostanoids, endothelin receptor blockers and phosphodiesterase 5 inhibitors. These treatment options can be combined at progression of the disease. Lung transplantation might be an option in patients refractory to medical therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21331640     DOI: 10.1007/s00108-011-2810-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

1.  [Diagnosis and treatment of pulmonary hypertension: European guidelines 2009].

Authors:  M M Hoeper; H A Ghofrani; M Gorenflo; E Grünig; D Schranz; S Rosenkranz
Journal:  Pneumologie       Date:  2010-05-18

2.  [Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010].

Authors:  H A Ghofrani; O Distler; F Gerhardt; M Gorenflo; E Grünig; W E Haefeli; M Held; M M Hoeper; C-M Kähler; H Kaemmerer; H Klose; V Köllner; B Kopp; S Mebus; A Meyer; O Miera; D Pittrow; G Riemekasten; S Rosenkranz; D Schranz; R Voswinckel; H Olschewski
Journal:  Dtsch Med Wochenschr       Date:  2010-09-22       Impact factor: 0.628

3.  Guidelines for the diagnosis and treatment of pulmonary hypertension.

Authors:  N Galiè; M M Hoeper; M Humbert; A Torbicki; J-L Vachiery; J A Barbera; M Beghetti; P Corris; S Gaine; J S Gibbs; M A Gomez-Sanchez; G Jondeau; W Klepetko; C Opitz; A Peacock; L Rubin; M Zellweger; G Simonneau
Journal:  Eur Respir J       Date:  2009-09-12       Impact factor: 16.671

4.  [Pulmonary hypertension: hemodynamic evaluation: hemodynamic evaluation – recommendations of the Cologne Consensus Conference 2010].

Authors:  C F Opitz; R Blindt; F Blumberg; M M Borst; L Bruch; H Leuchte; C Nagel; K Peters; S Rosenkranz; D Schranz; D Skowasch; M Lichtblau; H Tiede; J Weil; R Ewert
Journal:  Dtsch Med Wochenschr       Date:  2010-09-22       Impact factor: 0.628

5.  [Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010].

Authors:  E Grünig; A Barner; M Bell; M Claussen; M Dandel; D Dumitrescu; M Gorenflo; S Holt; G Kovacs; S Ley; J F Meyer; S Pabst; G Riemekasten; J Saur; M Schwaiblmair; C Seck; L Sinn; S Sorichter; J Winkler; H H Leuchte
Journal:  Dtsch Med Wochenschr       Date:  2010-09-22       Impact factor: 0.628

Review 6.  [Pulmonary hypertension: pathophysiology, genetics and functional genomics].

Authors:  O Eickelberg; W Seeger
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.